Bristol-Myers Squibb Co.'s (BMY) immuno-oncology agent Opdivo has been greenlighted by the FDA for yet another indication - this time, it is an accelerated approval for the treatment of patients with classical Hodgkin lymphoma who have relapsed or progressed after prior therapies like autologous stem cell transplant and Seattle Genetics' Adcetris.
from RTT - Biotech http://ift.tt/1TmKzgO
via IFTTT
No comments:
Post a Comment